A Phase I, Open-label, Uncontrolled, Multicenter, Dose-escalation Study of M3541 in Combination With Palliative Radiotherapy in Subjects With Solid Tumors

Trial Profile

A Phase I, Open-label, Uncontrolled, Multicenter, Dose-escalation Study of M3541 in Combination With Palliative Radiotherapy in Subjects With Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs M 3541 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors EMD Serono Research & Development Institute
  • Most Recent Events

    • 12 Mar 2018 Planned End Date changed from 25 Sep 2019 to 31 Dec 2019.
    • 12 Mar 2018 Planned primary completion date changed from 25 Mar 2019 to 3 Jul 2019.
    • 09 Jan 2018 Planned number of patients changed from 30 to 24.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top